Compounds > silybin
Page last updated: 2024-08-23

silybin and Carcinoma, Non-Small Cell Lung

silybin has been researched along with Carcinoma, Non-Small Cell Lung in 13 studies

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.69)29.6817
2010's9 (69.23)24.3611
2020's3 (23.08)2.80

Authors

AuthorsStudies
Bosch-Barrera, J; Cuyàs, E; Encinar, JA; Fernández-Arroyo, S; Joven, J; Menendez, JA; Verdura, S1
Gan, Y; Li, G; Ma, Y; Wang, A; Xu, S; Zhang, H1
Bae, SW; Jang, KJ; Jo, ES; Kang, DY; Lee, JM; Rugamba, A; Sp, N1
Agarwal, C; Agarwal, R; Chan, D; Mateen, S; Raina, K1
Agarwal, R; Mateen, S; Raina, K1
Barrajón-Catalán, E; Bonavia, R; Bosch-Barrera, J; Corominas-Faja, B; Cufí, S; Cuyàs, E; Joven, J; Martin-Castillo, B; Menendez, JA; Micol, V; Oliveras-Ferraros, C; Segura-Carretero, A; Vazquez-Martin, A; Visa, J2
Barrajón-Catalán, E; Bosch-Barrera, J; Corominas-Faja, B; Cuyàs, E; Joven, J; Martin-Castillo, B; Menendez, JA; Micol, V; Oliveras-Ferraros, C; Segura-Carretero, A1
Bosch-Barrera, J; Brunet, J; Cañete, N; Cuyàs, E; Haro, M; Izquierdo, A; Marruecos, J; Menendez, JA; Pedraza, S; Porta, R; Sais, E1
Bosch-Barrera, J; Cuyàs, E; Menendez, JA; Micol, V; Pérez-Sánchez, A1
Agarwal, C; Agarwal, R; Mateen, S; Singh, RP; Tyagi, A1
Agarwal, C; Agarwal, R; Chan, D; Jain, AK; Mateen, S; Raina, K1
Agarwal, C; Agarwal, R; Chan, DC; Dhanalakshmi, S; Mallikarjuna, GU; Sharma, G; Singh, RP; Tyagi, AK1

Reviews

1 review(s) available for silybin and Carcinoma, Non-Small Cell Lung

ArticleYear
Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer.
    Nutrition and cancer, 2013, Volume: 65 Suppl 1

    Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemoprevention; Disease Models, Animal; Epigenesis, Genetic; Humans; Lung Neoplasms; Silybin; Silymarin

2013

Other Studies

12 other study(ies) available for silybin and Carcinoma, Non-Small Cell Lung

ArticleYear
Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells.
    International journal of molecular sciences, 2022, Sep-01, Volume: 23, Issue:17

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Hepatocytes; Humans; Lactams; Lactams, Macrocyclic; Lipids; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Silybin; Tandem Mass Spectrometry; Triglycerides

2022
Silibinin suppresses epithelial-mesenchymal transition in human non-small cell lung cancer cells by restraining RHBDD1.
    Cellular & molecular biology letters, 2020, Volume: 25

    Topics: A549 Cells; Aged; Carcinoma, Non-Small-Cell Lung; Cell Movement; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Serine Endopeptidases; Silybin; Survival Rate

2020
Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells.
    Cells, 2021, 06-29, Volume: 10, Issue:7

    Topics: Apoptosis; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; ErbB Receptors; Human Umbilical Vein Endothelial Cells; Humans; Lung Neoplasms; Models, Biological; Neoplasm Invasiveness; Neoplastic Stem Cells; Neovascularization, Physiologic; Promoter Regions, Genetic; Protein Binding; Silybin; Spheroids, Cellular; STAT5 Transcription Factor

2021
Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells.
    The Journal of pharmacology and experimental therapeutics, 2013, Volume: 345, Issue:2

    Topics: Antioxidants; Azacitidine; Blotting, Western; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Decitabine; Drug Synergism; Enzyme Inhibitors; Epigenesis, Genetic; Gene Silencing; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; Hydroxamic Acids; Neoplasm Invasiveness; Silybin; Silymarin; Transcription Factors; Up-Regulation; Zinc Finger E-box-Binding Homeobox 1

2013
Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2013, Volume: 60

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Antioxidants; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Meglumine; Mice; Mice, Inbred NOD; Plant Extracts; Protein Kinase Inhibitors; Quinazolines; Seeds; Silybin; Silybum marianum; Silymarin; Tandem Mass Spectrometry; Xenograft Model Antitumor Assays

2013
Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo.
    Scientific reports, 2013, Volume: 3

    Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Mice; MicroRNAs; Protein Kinase Inhibitors; Quinazolines; Silybin; Silymarin; Treatment Outcome

2013
Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.
    Cell cycle (Georgetown, Tex.), 2013, Nov-01, Volume: 12, Issue:21

    Topics: Aldehyde Oxidoreductases; Antineoplastic Agents; Antioxidants; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Genotype; Humans; Lung Neoplasms; Mutation; Neoplastic Stem Cells; Phenotype; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Silybin; Silymarin; Spheroids, Cellular; Tumor Cells, Cultured

2013
Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin.
    Oncotarget, 2016, May-31, Volume: 7, Issue:22

    Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Brain Edema; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Compassionate Use Trials; Dietary Supplements; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Silybin; Silymarin; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2016
STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer.
    Cell cycle (Georgetown, Tex.), 2016, Dec-16, Volume: 15, Issue:24

    Topics: Anaplastic Lymphoma Kinase; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Gene Rearrangement; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Silybin; Silymarin; STAT3 Transcription Factor

2016
Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators.
    Molecular carcinogenesis, 2010, Volume: 49, Issue:3

    Topics: Antioxidants; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Humans; Lung Neoplasms; Silybin; Silymarin; Tumor Cells, Cultured

2010
Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.
    Epigenetics, 2012, Volume: 7, Issue:10

    Topics: Acetylation; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin B1; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Silybin; Silymarin; Vorinostat

2012
Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-15, Volume: 10, Issue:24

    Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Cell Proliferation; Cytosol; Doxorubicin; Drug Resistance, Neoplasm; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Protein Transport; Signal Transduction; Silybin; Silybum marianum; Silymarin; Transplantation, Heterologous; Tumor Cells, Cultured

2004